Results of preliminary phase II study of ublituximab in RRMS

Briumvi is an anti-CD20 monoclonal antibody approved for Clinically Isolated Syndrome, RRMS and active SPMS.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:
Contact MSUK

Results of preliminary phase II study of ublituximab in RRMS

Post by MSUK »

Rapid and robust B-cell depletion reported in preliminary phase II study of ublituximab

Relapsing remitting multiple sclerosis (RRMS) patients treated with ublituximab (TG-1101) have exhibited a median B-cell depletion of 99% at week four of an ongoing five month study, conducted by TG Therapeutics, Inc...Read more - http://www.ms-uk.org/rapid-and-robust-b ... mab-290617
MS-UK - http://www.ms-uk.org/
Top
User avatar
frodo
Family Elder
Posts: 1749
Joined: Wed Dec 02, 2009 3:00 pm
Contact:
Contact frodo

Re: Results of preliminary phase II study of ublituximab in

Post by frodo »

Thanks again. The news page of MS-UK is currently the best source of information in the web.
Top
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:
Contact MSUK

Re: Results of preliminary phase II study of ublituximab in

Post by MSUK »

Thank you for this feedback, means a lot :-D
MS-UK - http://www.ms-uk.org/
Top
Post Reply
  • Similar Topics
    Replies
    Views
    Last post

Return to “Briumvi (Ublituximab-xiiy)”